BioSpaceOriginal article
Gene therapy’s evidence problem—lessons from recent FDA decisions
RegulatoryrejectedNegative
AI Analysis
Summary
Recent FDA rejections in the cell and gene therapy space are highlighted through early-stage clinical trials from REGENXBIO, Excision BioTherapeutics, and Intellia Therapeutics, raising questions about evidence standards in the sector.
Clinical Trial Data
Phase
early-stage
Outcome Details
Recent FDA rejections in cell and gene therapy space
Importance:6/10
Sentiment:
-0.70
gene therapycell therapyFDA rejectionsclinical trialsregulatory
Read the original article
Published by BioSpace on May 4, 2026 1:23 PM